Barclays analyst Andrew Mok lowered the firm’s price target on Elevance Health (ELV) to $327 from $358 and keeps an Overweight rating on the shares following the Q2 report. The firm revised the company’s model post the earnings print.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Target downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Argus downgrades Elevance Health to Hold on ongoing profit pressures
- Elevance Health downgraded to Hold from Buy at Argus
- Elevance Health: Buy Rating Affirmed Amid Growth Potential in Non-HIX Segments and Temporary Earnings Boosts
- Insider Moves: Seagate, Elevance, Appian, AeroVironment, Box